Jitai Technology Reaches Strategic Cooperation with Eli Lilly Worth Up to US$1.1 Billion

On October 19, 2026, Jitai Technology (7666.HK) and Eli Lilly announced a strategic cooperation to jointly advance tissue-specific LNP delivery technology, with a total cooperation value of up to US$1.1 billion. Related reports described this as China's first major overseas deal for a generative AI-LNP platform. The reports also noted that Eli Lilly had previously established positions in areas including computing power, molecular design, gene editing, and in vivo delivery, and that this cooperation fills in the delivery layer; Jitai's NanoForge platform has accumulated more than 10 million lipid structures and 100,000 experimental data points, and its AiTEM platform had previously been locally deployed at Hengrui Pharmaceuticals. No subsequent progress has been disclosed so far.

AI-generated from public reports

1. Oct 19· 1 reports

   English translation is being prepared.

   Source:36Kr · AI